Draft guidance from NICE has recommended ranibizumab as an option for treating visual impairment caused by diabetic macular oedema (DMO). NICE conducted a rapid review of the original guidance, published in November 2011, because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses including the drug's superior relative effect among a sub-group of people with DMO.
The appraisal consultation document (ACD) makes the following recommendations:
1. Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only (Read more...)